Discovery of RAF265: A Potent mut-B-RAF Inhibitor for the Treatment of Metastatic MelanomaTeresa E. Williams, Daniel Poon, Sharadha Subramanian et al.|ACS Medicinal Chemistry Letters|2015Cited by 54
CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutationsPayman Amiri, Renhow Paul, Mina Aikawa et al.|Cancer Research|2006Cited by 25
Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase ActivatorChristopher G. Thomson, Savithri Ramurthy, Pengwei Pan et al.|Journal of Medicinal Chemistry|2024Cited by 16
Design and Synthesis of Orally Bioavailable Benzimidazole Reverse Amides as Pan RAF Kinase InhibitorsSharadha Subramanian, Savithri Ramurthy, Cynthia M. Shafer et al.|ACS Medicinal Chemistry Letters|2014Cited by 13
Abstract 6231: Activation of GCN2 by HC-7366 results in significant antitumor efficacy as monotherapy and in combination with multiple standard of care agents in various solid cancer modelsFeven Tameire, Nandita Bose, Paulina M. Wojnarowicz et al.|Cancer Research|2023Cited by 3